Literature DB >> 17134364

Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.

Lijo Simpson1, Evanthia Galanis.   

Abstract

Recurrent glioblastoma multiforme is a lethal disease with currently available treatment options having a limited impact on outcome. In this article, current and novel therapeutic approaches in the treatment of recurrent glioblastoma multiforme, including chemotherapy, targeted molecular agents, virotherapy/gene therapy and immunotherapy and challenges in developing novel therapeutic agents for glioblastoma multiforme will be discussed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17134364     DOI： 10.1586/14737140.6.11.1593

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  22 in total

1.  Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma.

Authors:  Zhenzhen Liu; Hongli Li; Lian He; Yu Xiang; Chengsen Tian; Can Li; Peng Tan; Ji Jing; Yanpin Tian; Lupei Du; Yun Huang; Leng Han; Minyong Li; Yubin Zhou
Journal:  Cell Chem Biol       Date:  2019-01-10       Impact factor: 8.116

2.  Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).

Authors:  Mateusz Opyrchal; Cory Allen; Ianko Iankov; Ileana Aderca; Mark Schroeder; Jann Sarkaria; Evanthia Galanis
Journal:  Hum Gene Ther       Date:  2012-03-09       Impact factor: 5.695

3.  Salvage therapy with single agent bendamustine for recurrent glioblastoma.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  J Neurooncol       Date:  2011-05-29       Impact factor: 4.130

4.  Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

Authors:  Antonio Silvani; Elena Lamperti; Paola Gaviani; Marica Eoli; Anna Fiumani; Andrea Salmaggi; Chiara Falcone; Graziella Filippini; Andrea Botturi; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2007-06-19       Impact factor: 4.130

5.  Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

Authors:  Cory Allen; Georgia Paraskevakou; Ianko Iankov; Caterina Giannini; Mark Schroeder; Jann Sarkaria; Mark Schroeder; Raj K Puri; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

6.  Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme.

Authors:  Jeffrey J Olson; Ellen McKenzie; Megan Skurski-Martin; Zhaobin Zhang; Daniel Brat; Surasak Phuphanich
Journal:  J Neurooncol       Date:  2008-08-05       Impact factor: 4.130

7.  Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

Authors:  Ayman I Omar; Warren P Mason
Journal:  Core Evid       Date:  2010-06-15

Review 8.  Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Authors:  David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

9.  Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.

Authors:  M Balducci; B Diletto; S Chiesa; G R D'Agostino; M A Gambacorta; M Ferro; C Colosimo; G Maira; C Anile; V Valentini
Journal:  Strahlenther Onkol       Date:  2014-01-17       Impact factor: 3.621

10.  Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma.

Authors:  Tejas Sankar; Zografos Caramanos; Rachid Assina; Jean-Guy Villemure; Richard Leblanc; Adrian Langleben; Douglas L Arnold; Mark C Preul
Journal:  J Neurooncol       Date:  2008-07-04       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.